Mixed xenogeneic porcine chimerism tolerizes human anti-pig natural antibody-producing cells in a humanized mouse model.


Journal

Xenotransplantation
ISSN: 1399-3089
Titre abrégé: Xenotransplantation
Pays: Denmark
ID NLM: 9438793

Informations de publication

Date de publication:
07 2021
Historique:
revised: 11 03 2021
received: 15 01 2021
accepted: 09 04 2021
pubmed: 28 4 2021
medline: 18 9 2021
entrez: 27 4 2021
Statut: ppublish

Résumé

A major obstacle to the success of organ transplantation from pigs to humans, necessitated by the shortage of human organs, is robust humoral immune rejection by pig-reactive human antibodies. Mixed xenogeneic hematopoietic chimerism induces xenoreactive B cell tolerance in rodents, but whether mixed pig/human chimerism could induce tolerance of human B cells to pig xenoantigens is unknown. We investigated this question using a humanized mouse model in which durable mixed (pig-human) xenogeneic chimerism can be established. Human natural anti-pig cytotoxic antibodies, predominantly IgM, are detectable in non-chimeric humanized mouse serum, and pig-reactive antibodies were reduced in mixed chimeric versus non-chimeric humanized mice. This difference required persistent mixed chimerism and was not due to the adsorption of antibodies on pig cells in vivo. Furthermore, human B cells from spleens of mixed chimeric mice produced lower levels of anti-pig antibodies when stimulated in vitro compared with those from non-chimeric mice. Our findings demonstrate that mixed chimerism reduces human natural antibodies to pig xenoantigens, providing the first in vivo evidence of human B cell tolerance induction by mixed xenogeneic chimerism and supporting further evaluation of this approach for inducing human B cell tolerance to xenografts.

Sections du résumé

BACKGROUND
A major obstacle to the success of organ transplantation from pigs to humans, necessitated by the shortage of human organs, is robust humoral immune rejection by pig-reactive human antibodies. Mixed xenogeneic hematopoietic chimerism induces xenoreactive B cell tolerance in rodents, but whether mixed pig/human chimerism could induce tolerance of human B cells to pig xenoantigens is unknown.
METHODS
We investigated this question using a humanized mouse model in which durable mixed (pig-human) xenogeneic chimerism can be established.
RESULTS
Human natural anti-pig cytotoxic antibodies, predominantly IgM, are detectable in non-chimeric humanized mouse serum, and pig-reactive antibodies were reduced in mixed chimeric versus non-chimeric humanized mice. This difference required persistent mixed chimerism and was not due to the adsorption of antibodies on pig cells in vivo. Furthermore, human B cells from spleens of mixed chimeric mice produced lower levels of anti-pig antibodies when stimulated in vitro compared with those from non-chimeric mice.
CONCLUSIONS
Our findings demonstrate that mixed chimerism reduces human natural antibodies to pig xenoantigens, providing the first in vivo evidence of human B cell tolerance induction by mixed xenogeneic chimerism and supporting further evaluation of this approach for inducing human B cell tolerance to xenografts.

Identifiants

pubmed: 33904221
doi: 10.1111/xen.12691
pmc: PMC8376778
mid: NIHMS1707585
doi:

Substances chimiques

Antigens, Heterophile 0

Types de publication

Journal Article Research Support, N.I.H., Extramural Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

e12691

Subventions

Organisme : NIAID NIH HHS
ID : R01 AI084903
Pays : United States
Organisme : NCRR NIH HHS
ID : S10 RR027050
Pays : United States
Organisme : NIAID NIH HHS
ID : P01 AI045897
Pays : United States
Organisme : NIH HHS
ID : S10RR027050
Pays : United States
Organisme : NIH HHS
ID : S10 OD020056
Pays : United States
Organisme : NIH HHS
ID : S10OD020056
Pays : United States

Informations de copyright

© 2021 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd.

Références

Xenotransplantation. 2013 Nov-Dec;20(6):458-68
pubmed: 24289469
Transplantation. 1976 Dec;22(6):559-67
pubmed: 137560
Proc Natl Acad Sci U S A. 2004 May 11;101(19):7335-40
pubmed: 15123792
Xenotransplantation. 2018 Sep;25(5):e12394
pubmed: 29604134
Transplantation. 2007 Apr 15;83(7):982-8
pubmed: 17460571
Transplantation. 2011 May 15;91(9):968-75
pubmed: 21403591
J Immunol. 1991 Dec 15;147(12):4140-6
pubmed: 1753089
Am J Transplant. 2017 Feb;17(2):353-364
pubmed: 27401926
Xenotransplantation. 2015 Mar-Apr;22(2):85-94
pubmed: 25308416
J Exp Med. 2016 Jan 11;213(1):93-108
pubmed: 26694971
Cold Spring Harb Perspect Med. 2014 Jan 01;4(1):a015529
pubmed: 24384815
Transplant Proc. 2000 Aug;32(5):1047
pubmed: 10936346
Blood. 2007 Feb 15;109(4):1773-81
pubmed: 17023586
Int J Surg. 2015 Nov;23(Pt B):217-222
pubmed: 26231992
Nat Methods. 2018 Aug;15(8):623-630
pubmed: 30065364
J Clin Invest. 1999 Aug;104(3):281-90
pubmed: 10430609
Am J Transplant. 2007 Sep;7(9):2090-7
pubmed: 17640313
Curr Opin Organ Transplant. 2018 Dec;23(6):642-648
pubmed: 30379724
Immunol Rev. 2014 Mar;258(1):241-58
pubmed: 24517437
Xenotransplantation. 2010 Jul-Aug;17(4):300-12
pubmed: 20723202
Hum Immunol. 2018 May;79(5):258-265
pubmed: 29175110
Blood. 2004 May 15;103(10):3964-9
pubmed: 14739221
Nat Med. 2005 Dec;11(12):1295-8
pubmed: 16311604
J Exp Med. 1998 Apr 20;187(8):1335-42
pubmed: 9547344
Int J Surg. 2015 Nov;23(Pt B):223-228
pubmed: 26306769
Am J Transplant. 2005 Dec;5(12):2821-9
pubmed: 16302994
Xenotransplantation. 2003 Mar;10(2):98-106
pubmed: 12588643
Blood. 2017 Feb 23;129(8):959-969
pubmed: 28077418
J Immunol. 2003 Nov 15;171(10):5406-14
pubmed: 14607944
Science. 2002 Feb 8;295(5557):1089-92
pubmed: 11778012
J Immunol. 1984 Jul;133(1):368-75
pubmed: 6609988
Xenotransplantation. 2000 Feb;7(1):58-64
pubmed: 10809058
Am J Pathol. 2008 Jun;172(6):1471-81
pubmed: 18467706
Science. 2003 Jan 17;299(5605):411-4
pubmed: 12493821
Transplant Proc. 1991 Feb;23(1 Pt 1):880-2
pubmed: 1990712
Sci Immunol. 2019 Nov 1;4(41):
pubmed: 31676497
Transplantation. 2001 Jun 15;71(11):1532-42
pubmed: 11435961
Curr Opin Organ Transplant. 2017 Dec;22(6):522-528
pubmed: 28937406
Xenotransplantation. 2011 Jan-Feb;18(1):1-5
pubmed: 21342282
Xenotransplantation. 2001 Nov;8(4):227-38
pubmed: 11737848
Transplant Proc. 1994 Jun;26(3):1197-8
pubmed: 8029884
Transpl Int. 2020 Jan;33(1):30-40
pubmed: 31705678
J Immunol. 1991 Jul 1;147(1):79-85
pubmed: 2051029
Xenotransplantation. 2020 Jan;27(1):e12552
pubmed: 31544995

Auteurs

Elizabeth E Waffarn (EE)

Department of Medicine, Columbia Center for Translational Immunology, College of Physicians and Surgeons, Columbia University, New York, NY, USA.

Mohsen Khosravi-Maharlooei (M)

Department of Medicine, Columbia Center for Translational Immunology, College of Physicians and Surgeons, Columbia University, New York, NY, USA.

Andrea Vecchione (A)

Department of Medicine, Columbia Center for Translational Immunology, College of Physicians and Surgeons, Columbia University, New York, NY, USA.

Steven Shao (S)

Department of Medicine, Columbia Center for Translational Immunology, College of Physicians and Surgeons, Columbia University, New York, NY, USA.

Paresh Vishwasrao (P)

Department of Medicine, Columbia Center for Translational Immunology, College of Physicians and Surgeons, Columbia University, New York, NY, USA.
Department of Hematology, Academic Medical Center, University of Amsterdam, Amsterdam, The Netherlands.

Markus A HÖlzl (MA)

Department of Medicine, Columbia Center for Translational Immunology, College of Physicians and Surgeons, Columbia University, New York, NY, USA.

Kristjana Frangaj (K)

Department of Medicine, Columbia Center for Translational Immunology, College of Physicians and Surgeons, Columbia University, New York, NY, USA.

Megan Sykes (M)

Department of Medicine, Columbia Center for Translational Immunology, College of Physicians and Surgeons, Columbia University, New York, NY, USA.

Hao Wei Li (HW)

Department of Medicine, Columbia Center for Translational Immunology, College of Physicians and Surgeons, Columbia University, New York, NY, USA.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH